Clinical trials: Stem Cell Mobilization
Severe Combined Immunodeficiency
Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
The goal of this study is to develop a novel approach to hematopoietic stem cell transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of toxic chemotherapy conditioning and…
- Trial name
- NCT01182675
- Testing
- Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Lymphoma, Non-Hodgkin, Multiple Myeloma
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) will be mobilized with chemotherapy and G-CSF plus plerixafor (AMD3100).
- Trial name
- NCT00322387
- Testing
- G-CSF and plerixafor
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, Multiple Myeloma
Lonquek for Autologous Stem Cell Mobilization
The aim of this study is to evaluate the efficacy and tolerability of Lonquek which is a pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells for autologous…
- Trial name
- NCT02488382
- Testing
- Lonquek
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Sheba Medical Center
Immunosuppression, Leukemia
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor s T cells (a type of lymphocyte, or white blood cell) have been removed and then added back.
- Trial name
- NCT00353860
- Testing
- SOLEX 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to…
- Trial name
- NCT00002674
- Testing
- filgrastim, cytarabine, etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Beta-Thalassemia
Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
Thalassemia is considered the most common genetic disorder worldwide, occurring with high frequency in Mediterranean areas, the Middle East, Southeast Asia, and the Pacific Islands.
- Trial name
- NCT01206075
- Testing
- Mozobil
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- University of Washington
Adenosine Deaminase Severe Combined Immune Deficiency
Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector
The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human…
- Trial name
- NCT05432310
- Testing
- A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Los Angeles
Multiple Myeloma, Bone Marrow Transplant Complications
Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma
Prospective, multicenter, observational registry of myeloma patients undergoing hematopoietic progenitor cell mobilization for upfront autologous transplantation.
- Trial name
- NCT03200626
- Testing
- Autologous hematopoietic cell transplant
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Medical College of Wisconsin
Healthy
AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation
Peripheral blood progenitor cells (PBPC) have become the preferred source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and shorter time required for engraftment.
- Trial name
- NCT00075335
- Testing
- AMD3100 (Mozobil plerixafor)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Malignant Lymphoma
Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma
Clinical Hypothesis: It is expected that by removing chemotherapy and adding ancestim to the mobilization scheme in most of the subjects sufficient PBPC will be harvested with a minimum of toxicity and side effects.
- Trial name
- SCF980266 (NCT01016795)
- Testing
- r-metHuSCF and Filgrastim, Chemotherapy plus Filgrastim
- Where
- 8 sites in Denmark, Finland and 2 more
- Volunteers
- 32 people
- Sponsor
- Aalborg University Hospital
Multiple Myeloma, Lymphoma
Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
Poor mobilization of hematopoietic progenitors needed to support autologous transplantation is a serious clinical problem. We are investigating the role of plerixafor administered in an at risk population to augment successful…
- Trial name
- NCT01037517
- Testing
- Plerixafor, Observation: Nonintervention
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- CancerCare Manitoba
Anterior Acute Myocardial Infarction, Left Ventricular Systolic Dysfunction
STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial
The purpose of this study is to demonstrate that granulocyte colony-stimulating factor (G-CSF) therapy in addition to state-of-the-art treatment (pharmacological and non pharmacological) is safe and significantly improves…
- Trial name
- STEM-AMI (NCT01969890)
- Testing
- G-CSF administration
- Where
- 53 sites in Italy
- Volunteers
- 532 people
- Sponsor
- Heart Care Foundation
Non-Hodgkin Lymphoma
Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma
The purpose of this study is to compare the ability of pegfilgrastim vs. filgrastim to mobilize peripheral blood stem cells in patients with Non Hodgkin-lymphoma in an intraindividual study
- Trial name
- NCT00306111
- Testing
- pegfilgrastim
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University Hospital Tuebingen
Hodgkin's Disease
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
Participants with Hodgkin's Disease (HD) who have been treated with cyto-reductive chemotherapy, who are to undergo autologous stem cell transplantation, and who meet the inclusion/exclusion criteria are eligible to enter this…
- Trial name
- NCT00396201
- Testing
- G-CSF Plus Plerixafor
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Autologous Haematopoietic Stem Cell Transplant
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients
This is a single-group treatment, phase IV, open label study to assess the mobilization efficacy and safety of plerixafor in combination with G- CSF in male and female participants from 18 to 75 years of age with multiple myeloma…
- Trial name
- NCT05087212
- Testing
- plerixafor + G-CSF
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sanofi
Stem Cells
Stem Cell Collection
This study is designed for the collection of stem cells from the bloodstream for use in research studies. These cells will be studied to determine if they have unique features particular to the donor that may or may not affect…
- Trial name
- NCT00316069
- Where
- United States
- Volunteers
- 429 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lymphoma
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
Primary Objectives: 1. To determine the efficacy of in vivo purging achieved by rituximab in the two groups. 2. To determine the number of apheresis procedures, total stem cell yield/kg patient body weight and the toxicity…
- Trial name
- NCT00499343
- Testing
- Etoposide, G-CSF, GM-CSF
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients
BKT-140 drug substance is a highly selective chemokine receptor (CXCR4) antagonist, which is developed by Biokine as a novel therapy for Multiple Myeloma (MM, a type of blood cancer).
- Trial name
- NCT01010880
- Testing
- BKT140
- Where
- 2 sites in Israel
- Volunteers
- 16 people
- Sponsor
- Biokine Therapeutics Ltd
Multiple Myeloma
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation
This study will examine whether 240 µg/kg plerixafor given alone for up to 4 days is safe and well tolerated in multiple myeloma (MM) patients.
- Trial name
- NCT00396383
- Testing
- plerixafor
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Genzyme, a Sanofi Company
RUNX1 Familial Platelet Disorder
Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
To evaluate the safety and feasibility of collecting hematopoietic stem cells (HSC) in participants with RUNX1-FPD.
- Trial name
- NCT06414889
- Testing
- G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center